Navigation Links
ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
Date:8/8/2008

Conference call scheduled for August 12, 2008 at 1:30 p.m. (Pacific);

simultaneous webcast at http://www.adventrx.com

SAN DIEGO, Aug. 8 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced that it will host a conference call with simultaneous webcast to discuss second quarter 2008 results on Tuesday, August 12th, 2008 at 1:30 p.m. Pacific / 4:30 p.m. Eastern. Evan M. Levine, Chief Executive Officer and President, and Mark N. K. Bagnall, Chief Financial Officer and Executive Vice President, will host the conference call.

The conference call may be accessed by dialing (888) 215-7027 for domestic callers and (913) 312-0654 for international callers. The webcast will be available live via the Internet by accessing ADVENTRX's website at http://www.adventrx.com under "Investors". Replays of the webcast will be available on ADVENTRX's website for 30 days and a phone replay will be available through September 12, 2008 by dialing (888) 203-1112 and entering the pass code 8240633.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. More information can be found on ADVENTRX's web site at http://www.adventrx.com.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ADVENTRX Settles Dispute With Former Licensee
2. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
3. ADVENTRX Appoints Vice President of Manufacturing
4. ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
7. Eric K. Rowinsky Joins ADVENTRX Board of Directors
8. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
9. ADVENTRX Announces Consolidation of Clinical and Management Positions
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. ADVENTRX Appoints Vice President of Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 PharmaBoardroom,s new ... today and available for free download , digs deep ... and growth in the sector today. One area ... has been in developing a homegrown pharmaceutical manufacturing base, even ... still remains some way off. A cursory comparison with neighboring ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), ... promotion of Nick Maroulis, Pharm.D. to the newly created ... , In this position, Dr. Maroulis will continue to ... directors of our multi-site pharmacies as the company expands. ... during that time he has served in many different ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... Pharma, Inc.,(Nasdaq: IDMI ), a biotechnology company focused ... Timothy P. Walbert,president and chief executive officer, will present ... Diego on Thursday, November 1, 2007,at 2 p.m. PDT ... webcast of the presentation will be available live and ...
... Immunosyn,Corporation (OTC Bulletin Board: IMYN) has announced the ... Financial and Accounting Officer.,Immunosyn,s former Chief Financial and ... as the company,s Chairman of the Board and,further ... believe that the platform technology and its resulting,biopharmaceutical ...
... Md., Oct. 29 /PRNewswire/,-- Cambridge Antibody Technology ... to,reflect AstraZeneca,s vision for its worldwide biologics ... resources and expertise from CAT, the pre-,existing ... AstraZeneca,Group, under the "MedImmune" name. With this ...
Cached Biology Technology:IDM Pharma to Present at BIOCOM Investor Conference 2IDM Pharma to Present at BIOCOM Investor Conference 3Immunosyn Corporation Names G. David Criner as CFO 2AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune 2
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ... Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter security ... 3.6% from 2014 to 2019. Although the U.S. market ... Canada is expected to grow at a ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 ... than the iPhone 5S, Samsung introduces for the ... The Galaxy S5 home button presents ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... expression of genes by turning them on or off at ... or cure of many diseases, say researchers at UT Southwestern ... of malfunctioning gene expression, or viral or bacterial gene expression," ... is an approach that could theoretically produce a drug for ...
... Vegetal of the Department of Agricultural Production at the ... for the best research in the area of viticulture. ... of Horticultural Science recently held in Oporto (Portugal). The ... grape varieties after a hydric stress event", studied the ...
... spent more than two decades leading efforts to combat ... relief supplies of antiretroviral therapies currently being distributed in ... those who can least afford to pay for them. ... of Public Health online June 28, infectious disease specialist ...
Cached Biology News:Gene silencing technique offers new strategy for treating, curing disease 2Best research work in the area of wine growing 2Hopkins AIDS experts issue warning about global efforts to provide drug therapies 2Hopkins AIDS experts issue warning about global efforts to provide drug therapies 3Hopkins AIDS experts issue warning about global efforts to provide drug therapies 4
Request Info...
... 2D polyacrylamide gel electrophoresis (2D-PAGE) with biological ... core technology platform for proteomic analysis. 2D-PAGE ... samples limited only in the dynamic range ... proteins. Quantitative image based analysis of separated ...
... Polymerase is ideal for high-fidelity amplification ... such as cloning and mutagenesis. ... proprietary enzyme preparation containing recombinant DNA ... (3'Cut Site5' exonuclease) activity. Platinum ...
... PLAU N-term Antibody This antibody is generated ... synthetic peptide selected within aa 50~150 of ... in PBS with 0.09% (W/V) sodium azide. ... G column and eluted out with both ...
Biology Products: